|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, until now only a handful number of genetic variants were reported to be associated with either nephropathy (ACE, ELMO1, FRMD3, and AKR1B1) or retinopathy (VEGF, AKR1B1, and EPO), and only a few studies were carried out for genetic susceptibility to cardiovascular diseases (ADIPOQ, GLUL) in patients with diabetes.
|
25169573 |
2014 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Aldose reductase appears to be involved in a variety of disease states other than diabetes, presumably due to its ability to catalyze the reduction of a broad spectrum of aldehydes, including some cytotoxic products of lipid peroxidation.
|
15736047 |
2005 |
|
Diabetes
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Upregulation of aldose reductase during foam cell formation as possible link among diabetes, hyperlipidemia, and atherosclerosis.
|
18451330 |
2008 |
|
Diabetes
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Specifically, the Z 2 allele, in the presence of diabetes and/or hyperglycemia, is associated with increased ALDR1 expression.
|
9709964 |
1998 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Prevention of diabetes-induced albuminuria in transgenic rats overexpressing human aldose reductase.
|
12166624 |
2002 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our previous work has implicated aldose reductase in a pathway whereby aldose reductase-induced use of nicotinamide adenine dinucleotide phosphate (reduced form) (NADPH) drives the pentose phosphate pathway, which culminates in a protein kinase C-induced increase in glomerular prostaglandin production and loss of mesangial cell contractility as a possible cause of hyperfiltration and glomerular dysfunction in diabetes.
|
10997684 |
2000 |
|
Diabetes
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
AR-TG mice homozygous for the transgene demonstrated a conditional cataract phenotype, whereby they developed lens vacuoles and cataract-associated structural changes only after induction of experimental diabetes; no such changes were observed in AR-TG heterozygotes or nontransgenic mice with or without experimental diabetes induction.
|
25541468 |
2015 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
A commentary on 10 years of aldose reductase inhibition for limited joint mobility in diabetes.
|
9442813 |
1998 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Aldose reductase (AR; gene AKR1B1) is the rate-limiting enzyme of the polyol pathway and has been associated with diabetes and atherosclerosis.
|
26873505 |
2016 |
|
Diabetes
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The commonly reported association of AKR1B1 with DR may be due to an association of the gene with younger age at onset of diabetes.
|
20424224 |
2010 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Diarylmethanon, bromophenol and diarylmethane compounds: Discovery of potent aldose reductase, α-amylase and α-glycosidase inhibitors as new therapeutic approach in diabetes and functional hyperglycemia.
|
30077669 |
2018 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Some of the compounds were found to possess excellent dual activity, hence they may be promising candidates to modify and evaluate their dual action, i.e., insulin release to combat diabetes and ALR2 inhibition to prevent/treat diabetic complications.
|
30818176 |
2019 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Aldose reductase (ALR), the first and rate-limiting enzyme involved in polyol pathway plays a central role in diabetes and its related complications, including diabetic retinopathy (DR).
|
27835059 |
2017 |
|
Diabetes
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The C-106T polymorphism was genotyped in 228 cases (microalbuminuria or overt proteinuria) and 220 controls (normoalbuminuria with diabetes duration > or =10 years) for a case-control comparison, and the association with erythrocyte AR content was investigated.
|
14582038 |
2003 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Increased glucose flux into the aldose reductase (AR) pathway during diabetes was reported to exert deleterious effects on the kidney.
|
28386557 |
2017 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Aldo-keto reductases (including AKR1B1 and AKR1B10) constitute a family of oxidoreductases that have been implicated in the pathophysiology of diabetes and cancer, including colorectal cancer (CRC).
|
28929377 |
2017 |
|
Diabetes
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Studies have shown that polymorphisms located at positions -106 and approximately -2100 base pairs (5'ALR2) in the regulatory region of the aldose reductase gene are associated with susceptibility to microvascular complications in patients with diabetes.
|
12943962 |
2003 |
|
Diabetes
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Mice have low levels of AR, thus raising them to human levels would be a more clinically relevant model to study changes in diabetes under atherosclerosis regression conditions.
|
29891593 |
2018 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Several of these activities, together with the effect of ellagic acid on insulin, glycogen, phosphatases, aldose reductase, sorbitol accumulation, advanced glycation end-product formation, and resistin secretion, may explain its effects on metabolic syndrome and diabetes.
|
29847844 |
2018 |
|
Diabetes
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
There was a highly significant increase in the frequency of the Z-2 5'ALR2 allele and Z-2/X (where X is not Z+2) genotype in patients with diabetic retinopathy (n = 159) compared with those without who had diabetes of 20 years' duration (uncomplicated, n = 70; chi(2) = 17.0, P < 0.0001).
|
11095596 |
2000 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Aldose reductase (ALR2), a NADPH-dependent aldo-keto reductase (AKR), is widely distributed in mammalian tissues and has been implicated in complications of diabetes, including diabetic nephropathy.
|
10944187 |
2000 |
|
Diabetes
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Indeed, AKR1B1 overexpression is related to diabetes secondary complications and, in some cases, with cancer.
|
29705708 |
2018 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Recent efforts to develop cure for chronic diabetic complications have led to the discovery of potent inhibitors against aldose reductase (AKR1B1, EC 1.1.1.21) whose role in diabetes is well-evident.
|
28917123 |
2017 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
According to previous research, aldose reductase (AR) plays a vital role in the oxidative stress-related complications of diabetes.
|
28057038 |
2017 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Aldose reductase (AR) is involved in the pathogenesis of diabetes, which is one of the major threats to global public health.
|
29792152 |
2019 |